{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T15:54:33Z","timestamp":1769356473024,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.yebeh.2024.109737","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T05:16:50Z","timestamp":1710998210000},"page":"109737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Utilization of APE2 and RITE2 scores in autoimmune encephalitis patients with seizures"],"prefix":"10.1016","volume":"154","author":[{"given":"Trevor","family":"Rafferty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Koeppen-Babcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikanth","family":"Muppidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-6685","authenticated-orcid":false,"given":"Scheherazade","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2024.109737_b0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jneuroim.2018.07.009","article-title":"Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction","volume":"323","author":"Dubey","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.yebeh.2024.109737_b0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2024.109737_b0015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s13311-019-00750-3","article-title":"Autoimmune epilepsy","volume":"16","author":"Husari","year":"2019","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.yebeh.2024.109737_b0020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"<scp>ILAE<\/scp> classification of the epilepsies: position paper of the <scp>ILAE<\/scp> Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2024.109737_b0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamaneurol.2016.5429","article-title":"Neurological autoantibody prevalence in epilepsy of unknown etiology","volume":"74","author":"Dubey","year":"2017","journal-title":"JAMA Neurol"},{"issue":"19","key":"10.1016\/j.yebeh.2024.109737_b0030","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1212\/WNL.0000000000007444","article-title":"Recognizing autoimmune encephalitis as a cause of seizures","volume":"92","author":"Britton","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.109737_b0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.seizure.2015.04.007","article-title":"Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy","volume":"29","author":"Dubey","year":"2015","journal-title":"Seizure"},{"issue":"12","key":"10.1016\/j.yebeh.2024.109737_b0040","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1586\/14737175.2015.1115720","article-title":"Immune therapy in autoimmune encephalitis: a systematic review","volume":"15","author":"Nosadini","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2024.109737_b0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2018.05.004","article-title":"Efficacy of antiepileptic drugs in autoimmune epilepsy: a systematic review","volume":"59","author":"Cabezudo-Garc\u00eda","year":"2018","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.yebeh.2024.109737_b0050","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/epi.13797","article-title":"Predictive models in the diagnosis and treatment of autoimmune epilepsy","volume":"58","author":"Dubey","year":"2017","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2024.109737_b0055","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/epi.16571","article-title":"Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions","volume":"61","author":"Steriade","year":"2020","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2024.109737_b0060","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1212\/01.wnl.0000187129.66353.13","article-title":"Serum antibodies in epilepsy and seizure-associated disorders","volume":"65","author":"McKnight","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2024.109737_b0065","doi-asserted-by":"crossref","first-page":"pp","DOI":"10.1136\/jnnp-2016-314758","article-title":"Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies","volume":"88","author":"Lang","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.yebeh.2024.109737_b0070","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ene.13180","article-title":"Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome","volume":"24","author":"Bien","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2024.109737_b0075","doi-asserted-by":"crossref","unstructured":"Ding S et al., \u201cValidation of Predictive Models of Autoimmune Encepahlitis-Related Antibodies to Cell-Surface Proteins Expressed in Neurons: A Retrospective Study Based in a Hospital,\u201d Front Neurol, vol. 12, pp. 1-8. doi: 10.3389\/fneur.2021.60161.","DOI":"10.3389\/fneur.2021.601761"},{"issue":"3","key":"10.1016\/j.yebeh.2024.109737_b0080","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/jnnp-2020-325011","article-title":"Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies","volume":"92","author":"McGinty","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"18","key":"10.1016\/j.yebeh.2024.109737_b0085","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1212\/WNL.0000000000000383","article-title":"Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy","volume":"82","author":"Toledano","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.yebeh.2024.109737_b0090","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/brain\/awx323","article-title":"The importance of early immunotherapy in patients with faciobrachial dystonic seizures","volume":"141","author":"Thompson","year":"2018","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.yebeh.2024.109737_b0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/WCO.0000000000000449","article-title":"Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis","volume":"30","author":"Spatola","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.yebeh.2024.109737_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00395","article-title":"Advances in autoimmune epilepsy associated with antibodies, their potential pathogenic Molecular mechanisms, and current recommended immunotherapies","volume":"8","author":"Fang","year":"2017","journal-title":"Front Immunol"},{"issue":"19","key":"10.1016\/j.yebeh.2024.109737_b0105","doi-asserted-by":"crossref","first-page":"e2185","DOI":"10.1212\/WNL.0000000000007475","article-title":"Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA B R encephalitis","volume":"92","author":"de Bruijn","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.109737_b0110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.seizure.2018.06.021","article-title":"Electroclinical features of seizures associated with autoimmune encephalitis","volume":"60","author":"Steriade","year":"2018","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/j.yebeh.2024.109737_b0115","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/epi.16282","article-title":"Seizure specificities in patients with antibody-mediated autoimmune encephalitis","volume":"60","author":"Vogrig","year":"2019","journal-title":"Epilepsia"},{"issue":"18","key":"10.1016\/j.yebeh.2024.109737_b0120","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0000000000002637","article-title":"The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies","volume":"86","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"issue":"03","key":"10.1016\/j.yebeh.2024.109737_b0125","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1055\/s-0038-1660860","article-title":"Autoimmune epilepsy: the evolving science of neural autoimmunity and its impact on epilepsy Management","volume":"38","author":"Quek","year":"2018","journal-title":"Semin Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2024.109737_b0130","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ana.26013","article-title":"Antibodies contributing to focal epilepsy signs and symptoms score","volume":"89","author":"Bruijn","year":"2021","journal-title":"Ann Neurol"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024001185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024001185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T23:14:14Z","timestamp":1714691654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024001185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":26,"alternative-id":["S1525505024001185"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109737","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of APE2 and RITE2 scores in autoimmune encephalitis patients with seizures","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109737"}}